U.S. Application No.: 10/520,784

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (Currently amended) A compound represented by the formula

$$\begin{array}{c|c} X & R^2 \\ \hline A & N & R^3 \\ \hline R^1 & 0 & \end{array}_{(I)}$$

wherein Ring A represents an optionally substituted pyridine ring, X represents an electron-attracting group, Y represents an optionally substituted divalent C₁₋₆ chained hydrocarbon group selected from the group consisting of a C₁₋₆ alkylene group, a C₂₋₆ alkenylene group, and a C₂₋₆ alkynylene group, R¹ represents an optionally substituted hydrocarbon group selected from the group consisting of aliphatic hydrocarbon group, alicyclic hydrocarbon group, alicyclic-aliphatic hydrocarbon group and aromatic hydrocarbon group, and R² and R³ each independently represent a hydrogen atom, an optionally substituted hydrocarbon group selected from the group consisting of aliphatic hydrocarbon group, alicyclic hydrocarbon group, alicyclic-aliphatic hydrocarbon group and aromatic hydrocarbon group or an optionally substituted heterocyclic group selected from the group consisting of a 5- to 14-membered (mono- to tricyclic) heterocyclic group containing 1 to 4 hetero atoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, or R² and R³ may form an optionally substituted ring together with an adjacent nitrogen atom, or a salt thereof.

U.S. Application No.: 10/520,784

2. (Original) The compound according to claim 1 which is a compound represented by the formula

$$\begin{array}{c|c}
X & R^2 \\
\hline
 & N & R^3
\end{array}$$

wherein Ring A" represents a pyridine ring which may have 1 to 3 substituents selected from a C_{1-4} alkyl group and a mono-, di- or tri-halogeno- C_{1-4} alkyl group and other symbols are as defined in claim 1, or a salt thereof.

- 3. (Original) The compound according to claim 1, wherein X is a nitrile group.
- 4. (Original) The compound according to claim 1, wherein Y is -CH=CH- or $-(CH_2)_2-$.
- 5. (Original) The compound according to claim 1, wherein R^1 is (1) a C_{5-7} cycloalkyl group optionally fused with a benzene ring, (2) a C_{7-19} aralkyl group, (3) a 5- or 6-membered heterocyclic ring- C_{1-4} alkyl group or (4) a C_{6-14} aryloxy- C_{1-4} alkyl group, each of which may have 1 to 4 substituents selected from a halogen atom, a C_{1-4} alkyl group, a mono-, dior tri-halogeno- C_{1-4} alkyl group and a C_{1-4} alkoxy group.
- 6. (Original) The compound according to claim 1, wherein one of R^2 and R^3 is a hydrogen atom or a C_{1-4} alkyl group, and the other is a 5- or 6-membered heterocyclic group, a C_{6-14} aryl group, a C_{7-19} aralkyl group, a C_{3-10} cycloalkyl group, a 5- or 6-membered heterocyclic ring- C_{1-4} alkyl group or C_{1-6} alkyl group, each of which may have 1 to 4 substituents selected from a halogen atom, a C_{1-4} alkyl group, a mono-, di- or tri-halogeno- C_{1-4} alkyl group, a C_{1-4}

U.S. Application No.: 10/520,784

alkoxy group, a C_{1-4} alkoxy-carbonyl group, a cyano group, a C_{1-4} alkyl-carbonylamino group and a hydroxy group; or R^2 and R^3 , together with an adjacent nitrogen atom, form a 5- or 6-membered nitrogen-containing heterocyclic ring optionally containing 1 to 3 hetero atoms selected from an oxygen atom, a sulfur atom and a nitrogen atom in addition to carbon atoms and one nitrogen atom, in which the nitrogen-containing heterocyclic ring may have 1 to 4 substituents selected from a halogen atom, a C_{1-4} alkyl group, a mono-, di- or tri-halogeno- C_{1-4} alkyl group, a C_{1-4} alkoxy group and a C_{1-4} alkoxy-carbonyl group.

- 7. (Original) (2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-(3,4-dimethoxyphenyl)prop-2-enamide,
- (2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-(3,4-dimethylphenyl)prop-2-enamide,
- (2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-methyl-N-phenylprop-2-enamide,
- (2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-(3-methylphenyl)prop-2-enamide,
- (2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-(4-hydroxy-3-methoxyphenyl)prop-2-enamide, or salts thereof.
 - 8. (Canceled)
- 9. (Currently amended) A medicine comprising the compound according to claim 1 or a prodrug thereof.
- 10. (Original) The medicine according to claim 9 which is a vanilloid receptor agonist.

U.S. Application No.: 10/520,784

11. (Original) The vanilloid receptor agonist according to claim 10 which is for local administration.

- 12. (Original) The vanilloid receptor agonist according to claim 10 which is an agent for preventing and/or treating overactive bladder.
- 13. (Original) The vanilloid receptor agonist according to claim 10 which is an analgesic.
- 14. (Currently amended) A method of preventing and/or treating overactive bladder, comprising administering to a mammal in need an effective amount of the compound according to claim 1 or a prodrug thereof.
- 15. (Currently amended) An analgesic method comprising administering to a mammal in need an effective amount of the compound according to claim 1 or a prodrug thereof.
- 16. (Withdrawn) Use of the compound according to claim 1 or a prodrug thereof for manufacturing an agent for preventing and/or treating overactive bladder.
- 17. (Withdrawn) Use of the compound according to claim 1 or a prodrug thereof for manufacturing an analgesic.